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(57) ABSTRACT 
Methods and devices are provided for targeted administration 
of a drug to a patient's eye. In one embodiment, the method 
includes inserting a hollow microneedle into the sclera of the 
eye at an insertion site and infusing a fluid drug formulation 
through the inserted microneedle and into the suprachoroidal 
space of the eye, wherein the infused fluid drug formulation 
flows within the suprachoroidal space away from the inser-
tion site during the infusion. The fluid drug formulation may 
flow circumferentially toward the retinochoroidal tissue, 
macula, and optic nerve in the posterior segment of the eye. 
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METHODS AND DEVICES FOR DRUG 
DELIVERY TO OCULAR TISSUE USING 
MICRO NEEDLE 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation of U.S. application Ser. 
No. 12/767,768, filedApr. 26, 2010, now U.S. Pat. No. 8,197, 
435, which is a continuation-in-part of U.S. application Ser. 
No. 11/743,535, filed May 2, 2007, now U.S. Pat. No. 7,918, 
814, issuedApr. 5, 2011, which claims benefit of U.S. Provi-
sional Application No. 60/746,237, filed May 2, 2006. Ben-
efit is also claimed to U.S. Provisional Application No. 
61/172,409, filedApr. 24, 2009. These applications are incor-
porated herein by reference. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made with U.S. govermnent support 
under Contract No. 8 ROI EB00260-03 and Contract No. 
2 
to provide methods for pinpoint delivery of drug to sclera, 
choroidal, uveal, macular, ciliary, vitreous and retinal tissues. 
SUMMARY OF THE INVENTION 
Methods and devices are provided for administering a drug 
to an eye of a patient. The methods may be used, for example, 
in the treatment of uveitis, glaucoma, diabetic macular 
edema, age-related macular degeneration, or cytomegalovi-
lO rus retinitis. In one aspect, the method includes inserting a 
hollow microneedle into the sclera of the eye at an insertion 
site, the microneedle having a tip end with an opening; and 
infusing over a period of time a fluid drug formulation, which 
15 
comprises a drug, through the inserted microneedle and into 
the suprachoroidal space of the eye, wherein during the 
period the infused drug formulation flows within the supra-
choroidal space away from the insertion site. 
20 BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. lA, lB, lC, and lD are cross-sectional illustrations 
R24EY017045-01, which were awarded by the National 
Institute of Health. The U.S. government has certain rights in 25 
the invention. 
of the tissue structures of a human eye. The eye as a whole 
(lA), a close-up of the cornea (lB), and a close-up of the 
sclera and associated tissues in an eye without fluid in the 
suprachoroidal space (1 C) or with fluid in the suprachoroidal 
space (lD). 
BACKGROUND OF THE INVENTION 
This invention is generally in the field of ophthalmic thera-
pies, and more particularly to the use of a microneedle for 
infusion of a fluid drug formulation into ocular tissues for 
targeted, local drug delivery. 
FIG. 2 is a cross-sectional view of a microneedle device 
comprising a hollow microneedle disposed in an elongated 
30 body according to one embodiment. 
The delivery of drug to the eye is extremely difficult, par-
ticularly delivery of macromolecules and delivery to the back 35 
of the eye. Many inflammatory and proliferative diseases in 
the posterior region of the eye require long term pharmaco-
logical treatment. Examples of such diseases include macular 
degeneration, diabetic retinopathy, and uveitis. It is difficult 
to deliver effective doses of drug to the back of the eye using 40 
conventional delivery methods such as topical application, 
which has poor efficacy, and systemic administration, which 
often causes significant side effects. (Geroski & Edelhauser, 
Invest. Ophthalmol. Vis. Sci. 41:961-64 (2000)). For example, 
while eye drops are useful in treating conditions affecting the 45 
exterior surface of the eye or tissues at the front of the eye, the 
eye drops cannot significantly penetrate to the back of the eye, 
as may be required for the treatment of various retinal dis-
eases. 
Direct injection into the eye, using conventional needles 50 
and syringes is often effective, but requires professional train-
ing and raises concerns about safety (Maurice, J. Ocul. Phar-
macol. Ther. 17:393-401 (2001 )). It also would be desirable to 
FIG. 3 is a cross-sectional view of the elongated body of the 
microneedle devices shown in FIG. 2. 
FIG. 4 is an illustration of a microneedle device according 
to one embodiment. 
FIG. 5 is an illustration of a microneedle device according 
to one embodiment. 
FIGS. 6A and 6B illustrate an embodiment of a process for 
using a hollow microneedle to deliver drug into the supracho-
roidal space of an eye, where the process includes inserting 
the hollow microneedle into the sclera and infusion of a fluid 
drug formulation into the suprachoroidal space. 
FIG. 7A shows a comparison of a hollow microneedle 
according to one embodiment as compared to the tip of a 
conventional 30 gauge hypodermic needle. FIG. 7B shows a 
schematic illustration of a custom acrylic mold shaped to fit a 
whole eye. 
FIGS. SA and SB are brightfield microscopic images of 
saggital cross sections of a pig eye before and after infusion of 
sulforhadamine, respectively. 
FIGS. 9A, 9B, 9C, and 9D are fluoroscopic images of a 
cryosection of a pig eye with no infusion into the suprachor-
oidal space (9A), a cryosection of a rabbit eye after infusion of 
500 nm fluorescent particles in the axial plan and collaged to 
form a panoramic view (9B), a cryosection of a pig eye after be able to minimize the number and/or frequency of eye 
injection treatments needed to deliver therapeutically effec-
tive amounts of drug to the ocular tissue sites that need it. 
The suprachoroidal space of the eye has been studied, and 
its cannulation described as a possible route for drug delivery. 
See, e.g., Olsen, et al., American J. Ophthalmology 142(5): 
777-87 (November 2006); PCT Patent Application Publica-
tion No. WO 2007 /100745 to I science Interventional Corpo-
ration. 
55 infusion of 500 nm fluorescent particles in the saggital direc-
tion and collaged to show the spaces both anterior and poste-
rior to the microneedle insertion site (9C), and a cryosection 
of a human eye after infusion of 500 nm fluorescent particles 
in the saggital direction and collaged to show spaces both 
It therefore would be desirable to provide better, safer, 
more effective techniques for the direct delivery of therapeu-
tic agents to eye tissues. It also would be desirable to provide 
devices useful in such techniques which can be relatively 
inexpensive to produce and use. It further would be desirable 
60 anterior and posterior to the microneedle insertion site (9D). 
The insets of FIGS. 9B, 9C, and 9D show magnified views of 
the microneedle insertion site. 
FIGS. lOA and lOB are microcomputed tomography 
images showing the circumferential spread of 1 µm contrast 
65 particles infused into the suprachoroidal space of a pig eye in 
a cross-sectional image (lOA) and a three-dimensional recon-
struction of the cross-sectional images (lOB). 
US 8,636,713 B2 
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FIGS. llA, llB, llC, and llD are graphs showing the 
effect of infusion pressure and microneedle length on the 
success rate of suprachoroidal delivery of 20 nm particles 
(llA), 100 nm particles (llB), 500 nm particles (llC), and 
1000 nm particles (llD) into pig eyes. 
FIGS. 12A and 12B are fluoroscopic images of a cryosec-
tion of a pig eye after infusion of 20 nm particles (12A) and 
1000 nm particles (12B) in the saggital direction and collaged 
to show spaces both anterior and posterior to the microneedle 
insertion site. The insets of FIGS. 12A and 12B show mag-
nified views of the microneedle insertion site. 
FIGS. 13A and 13B are graphs showing the effect of the 
intraocular pressure and microneedle length on the success 
rate of suprachoroidal delivery of 1000 nm particles for a 
simulated intraocular pressure of 18 mmHg (13A) and 36 
mmHg (13B). 
FIG. 14 is a one-dimensional line of sight scan of rabbit 
eyes taken after injection of sodium fluorescein to the supra-
choroidal space, with the x-axis representing the position in 
the eye from back (0) to front (160) and the y-axis represent-
ing the fluorescent intensity at that position. 
FIG. 15 is a graph showing the rate of clearance of sodium 
fluorescein from the suprachoroidal space over time. 
FIG. 16 is a graph showing the rate of clearance of 20 nm 
particles from the suprachoroidal space over time. 
FIG. 17 is a graph showing the rate of clearance of 500 nm 
particles from the suprachoroidal space over time. 
FIG. 18 is a block diagram of a method for administering a 
drug to the eye according to one embodiment. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
An effective drug delivery system for delivery of a drug to 
the eye should optimally embody four general characteristics: 
first, it should be minimally invasive and safe; second, the 
drug should be administered in such a way that it is well 
targeted to the desired tissues and limits exposure to other 
regions of the eye; third, it should be capable of controlled or 
sustained delivery of the drug; and fourth, it should be as 
simple to use as possible. Embodiments of the present 
description address these needs by providing microneedle 
devices and methods of use to enhance the delivery of a drug 
to the eye. 
4 
Microneedles enable this delivery to be done in a mini-
mally invasive manner superior to conventional needle 
approaches. For instance, the present microneedles advanta-
geously may be inserted perpendicularly into the sclera, 
reaching the suprachoroidal space in a short penetration dis-
tance. This is in contrast to long conventional needles or 
cannula which must approach the suprachoroidal space at a 
steep angle, taking a longer penetration path through the 
sclera and other ocular tissue, increasing the size of the needle 
10 track and consequently increasing the risk ofinfection and/or 
vascular rupture. With such long needles, the ability to pre-
cisely control insertion depth is diminished relative to the 
microneedle approach described herein. 
Advantageously, the delivery of the drug into the supra-
15 choroidal space allows for the delivery of fluid drug formu-
lation over a larger tissue area and to more difficult to target 
tissues in a single administration as compared to previously 
known needle devices. Not wishing to be bound by any 
theory, it is believed that upon entering the suprachoroidal 
20 space the fluid drug formulation flows circumferentially from 
the insertion site toward the retinochoroidal tissue, macula, 
and optic nerve in the posterior segment of the eye as well as 
anteriorly toward the uvea and ciliary body. In addition, a 
portion of the infused fluid drug formulation may remain in 
25 the sclera near the microneedle insertion site, serving as addi-
tional depot of the drug formulation that subsequently can 
diffuse into the suprachoroidal space and then into other 
adjacent tissues. 
As used herein, the term "suprachoroidal space," which is 
30 synonymous with suprachoroid or suprachoroidia, describes 
the potential space in the region of the eye disposed between 
the sclera and choroid. This region primarily is composed of 
closely packed layers of long pigmented processes derived 
from each of the two adjacent tissues; however, a space can 
35 develop in this region as a result of fluid or other material 
buildup in the suprachoroidal space and the adjacent tissues. 
Those skilled in the art will appreciate that the suprachoroidal 
space frequently is expanded by fluid buildup because of 
some disease state in the eye or as a result of some trauma or 
40 surgical intervention. In the present description, however, the 
fluid buildup is intentionally created by infusion of a drug 
formulation into the suprachoroid to create the suprachoroi-
dal space (which is filled with drug formulation). Not wishing 
to be bound by any theory, it is believed that this region serves 
45 as a pathway for uveoscleral outflow (i.e., a natural process of 
the eye moving fluid from one region of the eye to the other 
through) and becomes a real space in instances of choroidal 
detachment from the sclera. 
In one advantageous and exemplary embodiment of the 
methods described herein, delivery of a drug is achieved by 
injecting (inserting) a microneedle into the sclera and inject-
ing (infusing) a drug formulation through the inserted 
microneedle and into the suprachoroidal space of the eye. The 50 
microneedle is able to precisely deliver the drug into the 
suprachoroidal space for subsequent local delivery to nearby 
tissues in need of treatment. The drug may be released into the 
ocular tissues from the infused volume (or, e.g., from the 
microparticles therein) for an extended period, e.g., several 
hours or days or weeks or months, after the microneedle has 
been inserted and withdrawn. This beneficially can provide 
increased bioavailability of the drug relative, for example, to 
delivery by topical application of the drug formulation to 
ocular tissue surfaces. With the present microneedle, the 60 
method advantageously includes precise control of the depth 
Methods of Using the Microneedle 
The microneedle devices described herein may be used to 
deliver drug formulations to the eye of a patient, particularly 
for the treatment, diagnosis, or prevention of ocular diseases. 
In a preferred embodiment, the patient is a human patient in 
need of treatment. The patient may be an adult or a child. In 
55 other embodiments, the patient may be a non-human mam-
mal. 
A wide range of ocular diseases and disorders may be 
treated by the methods and devices described herein. Non-
limiting examples of ocular diseases include uveitis, glau-
coma, diabetic macular edema or retinopathy, macular degen-
eration, and genetic diseases. The methods described herein 
are particularly useful for the local delivery of drugs that need 
to be administered to the posterior region of the eye, for 
example the retinochoroidal tissue, macula, and optic nerve in 
the posterior segment of the eye. In one embodiment, the 
delivery methods and devices described herein may be used in 
gene-based therapy applications. For example, the methods 
of insertion into the ocular tissue, so that the microneedle tip 
can be placed into the suprachoroidal space or in the sclera but 
near enough to the suprachoroidal space for the infused drug 
formulation to flow into the suprachoroidal space. Advanta- 65 
geously, this may be accomplished without contacting under-
lying tissues, such as choroid and retina tissues. 
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may administer a fluid drug formulation into the suprachor-
oidal space to deliver select DNA, RNA, or oligonucleotides 
to targeted ocular tissues. 
The microneedles can be used to target delivery to specific 
tissues or regions within the eye or in neighboring tissue. In 
various embodiments, the methods may be designed for drug 
delivery specifically to the sclera, the choroid, the Bruch's 
membrane, the retinal pigment epithelium, the subretinal 
space, the retina, the macula, the optic disk, the optic nerve, 
the ciliary body, the trabecular meshwork, the aqueous 10 
humor, the vitreous humor, and other ocular tissue or neigh-
boring tissue in need of treatment. 
As used herein, "ocular tissue" and "eye" 10 include both 
the anterior segment 12 of the eye (i.e., the portion of the eye 
in front of the lens) and the posterior segment 14 of the eye 15 
(i.e., the portion of the eye behind the lens), as illustrated in 
FIG. lA. The anterior segment 12 is bounded by the cornea 16 
and the lens 18, while the posterior segment 14 is bounded by 
the sclera 20 and the lens 18. The anterior segment 12 is 
further subdivided into the anterior chamber 22, between the 20 
iris 24 and the cornea 16, and the posterior chamber 26, 
between the lens 18 and the iris 24. The exposed portionofthe 
sclera 20 on the anterior segment 12 of the eye is protected by 
6 
depth is limited by the selected length or effective length of 
the microneedle. The "effective length" is that portion avail-
able for tissue insertion, i.e., the length that extends from the 
base and would be inserted ifthere were zero tissue deforma-
tion; it neglects any proximal portion of the microneedle that 
extends into or through the base and thus carmot be inserted in 
the tissue. That is, the microneedle may have a length 
approximately equal to the desired penetration depth. In one 
embodiment, the microneedle is short enough that tip of the 
microneedle may be inserted substantially to the base of the 
sclera (i.e., near the interface of the sclera and choroid) with-
out completely penetrating across the sclera. In another 
embodiment, the tip of the microneedle is inserted through 
the sclera into the suprachoroidal space without penetrating 
through the choroid. 
In another embodiment, the microneedles are designed to 
have a length longer than the desired penetration depth, but 
the microneedles are controllably inserted only part way into 
the tissue. Partial insertion may be controlled by the mechani-
cal properties of the tissue, which bends and dimples during 
the microneedle insertion process. In this way, as a micron-
eedle is inserted into the tissue, its movement partially elas-
tically deforms the tissue and partially penetrates into the 
tissue. By controlling the degree to which the tissue deforms, 
the depth of microneedle insertion into the tissue can be 
controlled. 
Additional insertion control features are described below 
in the "Control Features for Directing Movement of the 
Microneedle in the Methods of Use" section below. 
In another embodiment, a microneedle is inserted into the 
tissue using a rotational/drilling technique and/or a vibrating 
action. In this way, the microneedle can be inserted to a 
desired depth by, for example, drilling the microneedles a 
desired number of rotations, which corresponds to a desired 
a clear membrane referred to as the conjunctiva (not shown). 
Underlying the sclera 20 is the choroid 28 and the retina 27, 25 
collectively referred to as retinachoroidal tissue. The loose 
connective tissue, or potential space, between the choroid 28 
and the sclera 20 is referred to as the suprachoroidal space 
(not shown). FIG. lB illustrates the cornea 16, which is com-
posed of the epithelium 30, the Bowman's layer 32, the 30 
stroma 34, the Descemet's membrane 36, and the endothe-
lium 38. FIG. lC and FIG. lD illustrate the sclera 20 with 
surrounding Tenon's Capsule 40 or conjunctiva 41, supracho-
roidal space 42, choroid 28, and retina 27, both without and 
with a fluid in the suprachoroidal space, respectively. 35 depth into the tissue. See, e.g., U.S. Patent Application Pub-
lication No. 20050137525 Al to Wang et al., which is incor-
porated herein by reference, for a description of drilling 
microneedles. The rotational/drilling technique and/or a 
vibrating action may be applied during the insertion step, 
The method of administering a drug to the eye generally 
comprises the steps ofinserting a hollow microneedle into the 
sclera and then infusing a fluid drug formulation through the 
hollow microneedle and into the suprachoroidal space of the 
eye. 
Insertion 
In one embodiment, the insertion site is between the equa-
tor and the limbus of the eye. In another embodiment, the 
insertion site is between about 2 mm and about 10 mm pos-
terior to the limbus of the eye. In embodiments, the insertion 
site of the microneedle is at about the equator of the eye. In 
another embodiment, the insertion site is between the equator 
and the limbus of the eye. In another embodiment, the inser-
tion site is from 2 to 10 mm posterior to the limbus of the eye. 
40 retraction step, or both. 
Infusion 
In a preferred embodiment, the fluid drug formulation is 
infused into the suprachoroidal space through a hollow 
microneedle by driving the drug formulation from a source 
45 reservoir into the ocular tissue using a pressure gradient (e.g., 
pumping, syringe). In other embodiments, the drug formula-
tion may be driven from a source reservoir into the ocular 
tissue using an electric field (e.g., iontophoresis) or another 
externally applied energy (e.g., ultrasound/acoustic energy). 
In another embodiment, the drug formulation is introduced 50 
into the suprachoroidal space at the site ofinjection (i.e., at the 
In one embodiment, the amount of fluid drug formulation 
infused into the suprachoroidal space from the inserted 
microneedle is from 10 microliterto 200 microliter, e.g., from 
50 to 150 µL. In another embodiment, from about 10 micro-
literto about 500 micro liter, e.g., from 50 to 250 µL, is infused 
tip of the microneedle) and then flows through the supracho-
roidal space away from the site ofinjection while the injection 
occurs. In another embodiment, the site of injection (i.e., at 
the tip of the microneedle) is anterior to the equator of the eye 
and at least a portion of the drug formulation flows posterior 
to the equator of the eye during the injection (i.e., while drug 
formulation continues to flow out of the microneedle). In 
another embodiment, the site of injection (i.e., at the tip of the 
microneedle) is anterior to the equator of the eye and at least 
a portion of the drug formulation flows near the macular 
during the injection (i.e., while drug formulation continues to 
flow out of the microneedle). 
Importantly, the depth of insertion of the microneedle into 
the ocular tissue is precisely controlled. Various methods can 
be used to control the insertion depth of the microneedles 
described herein. In a particular embodiment, the insertion 
55 through the microneedle into the suprachoroidal space. 
In one embodiment, the driving force or pressure infusing 
the fluid drug formulation through the microneedle causes the 
infused drug formulation to flow within the suprachoroidal 
space and reach the back of the eye during the administration 
60 (i.e., during the infusion) process. This may occur in less than 
one or two minutes, such as 1 sec to 100 sec, e.g., 10 to 30 
seconds. In one aspect, the fluid drug formulation desirably 
flows circumferentially within the suprachoroidal space dur-
ing the infusion process to a site that is at least 2.5 mm away 
65 from the insertion site, to a site that is at least 5 mm away from 
the insertion site, or to a site that is at least 10 mm away from 
the insertion site. Desirably, the fluid drug formulation flows 
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circumferentially within the suprachoroidal space from the 
insertion site toward the back of the eye (i.e., the retinochor-
oidal tissue, macula, and optic nerve in the posterior segment 
of the eye). 
The amount of drug delivered within the ocular tissue also 
may be controlled, in part, by the type of microneedle used 
and how it is used. In one exemplary embodiment, a hollow 
microneedle is inserted into the ocular tissue and progres-
sively retracted from the ocular tissue after insertion to deliver 
a fluid drug, where after achieving a certain dosage, the deliv- 10 
ery could be stopped by deactivating the fluid driving force, 
such as pressure (e.g., from a mechanical device such as a 
syringe) or an electric field, to avoid leakage/uncontrolled 
deliver of drug. Desirably, the amount of drug being delivered 
is controlled by driving the fluid drug formulation at a suitable 15 
infusion pressure. In certain embodiments, the infusion pres-
sure may be at least 150 kPa, at least 250 kPa, or at least 300 
kPa. Suitable infusion pressures may vary with the particular 
patient or species. 
Those skilled in the art will appreciate, however, that the 20 
desired infusion pressure to deliver a suitable amount of fluid 
drug formulation may be influenced by the depth of insertion 
of the microneedle and the composition of the fluid drug 
formulation. For example, a greater infusion pressure may be 
required in embodiments wherein the drug formulation for 25 
delivery into the eye is in the form of or includes nanoparticles 
or microparticles encapsulating the active agent or 
microbubbles. Nanoparticle or microparticle encapsulation 
techniques are well known in the art. 
Additional infusion control features are described below in 30 
the "Control of Transport Through Microneedle" section 
below. 
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possible to minimize patient discomfort-in contrast to trans-
dermal microneedle patch applications, where patches may 
more likely be worn (with microneedles inserted) over an 
extended period without patient discomfort. 
Other Steps, Embodiments, and Applications 
In another aspect, the method of administering a drug to an 
eye of a patient may include monitoring the insertion of the 
microneedle and/or infusion of the fluid drug formulation to 
ensure precise delivery of the fluid drug formulation to the 
suprachoroidal space (FIG. 18). Such monitoring may be 
achieved using imaged-guided feedback methods during one 
or more of these steps, non-limiting examples of which 
include conventional microscopy, MRI, x-ray, confocal 
microscopy, ocular coherence tomography (e.g., anterior seg-
ment optical coherence tomography, Heidelberg retina 
tomography, spectral domain optical coherence tomogra-
phy), fluorescein angiography, indocyanine green angiogra-
phy, high resolution stereoscopic fundus photography, autof-
luorescence imaging, ultra-wide field imaging, and various 
ultrasound techniques. Thus, the method may further com-
prise determining whether an initial infusion of the fluid drug 
formulation has flowed into the suprachoroidal space of the 
eye and away from the insertion site. Ifit is determined that an 
initial infusion has been successful, a desired volume of the 
fluid drug formulation can be infused and the infusion dis-
continued by removing the fluid driving force, such as pres-
sure, and retracting the microneedle from the eye. If, however, 
it is determined that the initial infusion of the fluid drug 
formulation has been unsuccessful (i.e., substantially none of 
the drug formulation has flowed into the suprachoroidal space 
of the eye and away from the insertion site), then the micron-
eedle may be repositioned and the process repeated until a 
successful delivery is achieved. 
The microneedle optionally may be part of an array of two 
35 or more microneedles such that the method further includes 
In one embodiment, the method of administering a drug to 
the eye may further include partially retracting the hollow 
microneedle after the insertion step and before and/or during 
the infusion of the drug formulation. In a particular embodi-
ment, the partial retraction of the microneedle occurs prior to 
the step of infusing the fluid drug formulation into the ocular 
tissue. This insertion/retraction step may form a pocket and 
beneficially permits the fluid drug formulation to flow out of 40 
the microneedle unimpeded or less impeded by ocular tissue 
at the opening at the tip portion of the microneedle. This 
pocket may be filled with drug formulation, but also serves as 
a conduit through with fluid drug formulation can flow from 
the microneedle, through the pocket and into the suprachor- 45 
oidal space. FIG. 6A shows a hollow microneedle 130 
inserted into the sclera 20, with drug formulation 131 tempo-
rarily positioned in the hollow bore of the microneedle. (The 
fluid communication to a reservoir of the fluid drug formula-
tion is not shown.) FIG. 6B shows the microneedle 130 fol- 50 
lowing partial retraction and infusion of the fluid drug formu-
lation 131 into the suprachoroidal space. Arrows show the 
circumferential flow of the drug formulation through the 
suprachoroidal space. 
inserting at least a second microneedle into the sclera without 
penetrating across the sclera. In one embodiment wherein an 
array of two or more microneedles are inserted into the ocular 
tissue, the drug formulation of each of the two or more 
microneedles may be identical to or different from one 
another, in drug formulation, volume/quantity of drug formu-
lation, or a combination of these parameters. In one case, 
different types of drug formulations may be injected via the 
one or more microneedles. For example, inserting a second 
hollow microneedle comprising a second drug formulation 
into the ocular tissue will result in delivery of the second drug 
formulation into the ocular tissue. 
The microneedle devices described herein may be adapted 
to remove substances, such as a fluid, tissue, or molecule 
sample, from the eye. 
Those skilled in the art will appreciate, however, that other 
types of microneedles solid microneedles) and other methods 
of delivering the drug formulation into the ocular tissue, may 
be used instead of or in conjunction with the infusion methods 
described herein. Non limiting examples include dissolving, 
at least in part, a coating of a drug formulation off of a 
microneedle; detaching, at least in part, a coating of a drug 
formulation (e.g., as a substantially intact sleeve or in frag-
ments) off ofa microneedle; breaking or dissolving a micron-
eedle off of a base to which the microneedle is integrally 
formed or is connected; or any combination thereof. 
In a particular embodiment, the microneedle infuses a drug 55 
formulation through the sclera into the suprachoroidal space 
for controlled (i.e., sustained, extended, or modulated over 
time) release of a drug to one or more ocular or neighboring 
tissues. This "sustained release" or "extended release" or 
"modulated release" is generally more prolonged than that 60 
obtainable by topical application of the drug formulation to 
the ocular tissue. In a particular embodiment, there is an 
extended, sustained or modulated release of the drug formu-
lation after at least one microneedle is withdrawn from the 
ocular tissue. This delivery method can be particularly advan-
tageous with ocular tissues, where it is desirable for the inser-
tion and withdrawal process to occur over as short a period as 
The microneedle devices described herein also may be 
adapted to use the one or more microneedles as a sensor to 
detect analytes, electrical activity, and optical or other sig-
65 nals. The sensor may include sensors of pressure, tempera-
ture, chemicals, and/or electromagnetic fields (e.g., light). 
Biosensors can be located on or within the microneedle, or 
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inside a device in connnunication with the body tissue via the 
microneedle. The microneedle biosensor can be any of the 
four classes of principal transducers: potentiometric, ampero-
metric, optical, and physiochemical. In one embodiment, a 
hollow microneedle is filled with a substance, such as a gel, 
that has a sensing functionality associated with it. In an appli-
cation for sensing based on binding to a substrate or reaction 
mediated by an enzyme, the substrate or enzyme can be 
immobilized in the needle interior. In another embodiment, a 
wave guide can be incorporated into the microneedle device 
to direct light to a specific location, or for detection, for 
example, using means such as a pH dye for color evaluation. 
Similarly, heat, electricity, light, ultrasound or other energy 
forms may be precisely transmitted to directly stimulate, 
damage, or heal a specific tissue or for diagnostic purposes. 
The Microneedle Device 
The microneedle device includes a hollow microneedle. 
The device may include an elongated housing for holding the 
proximal end of the microneedle. The device may further 
include a means for conducting a fluid drug formulation 
through the microneedle. For example, the means may be a 
flexible or rigid conduit in fluid connection with the base or 
proximal end of the microneedle. The means may also 
include a pump or other devices for creating a pressure gra-
dient for inducing fluid flow through the device. The conduit 
may in operable connection with a source of the fluid drug 
formulation. The source may be any suitable container. In one 
embodiment, the source may be in the form of a conventional 
syringe. The source may be a disposable unit dose container. 
Microneedle 
10 
10 
have an aspect ratio (width: length) of about 1: 1.5 to about 
1: 10. Other lengths, widths, and aspect ratios are envisioned. 
The microneedle can have a straight or tapered shaft. In one 
embodiment, the diameter of the microneedle is greatest at 
the base endofthemicroneedle and tapers to a point at the end 
distal the base. The microneedle can also be fabricated to have 
a shaft that includes both a straight (i.e., untapered) portion 
and a tapered (e.g., beveled) portion. The microneedles can be 
formed with shafts that have a circular cross-section in the 
perpendicular, or the cross-section can be non-circular. The 
tip portion of the microneedles can have a variety of configu-
rations. The tip of the microneedle can be symmetrical or 
asynnnetrical about the longitudinal axis of the shaft. The tips 
15 may be beveled, tapered, squared-off, or rounded. In particu-
lar embodiments, the microneedle may be designed such that 
the tip portion of the microneedle is substantially the only 
portion of the microneedle inserted into the ocular tissue (i.e., 
the tip portion is greater than 75% of the total length of the 
20 microneedle, greater than 85% of the total length of the 
microneedle, or greater than about 95% of the total length of 
the microneedle ). In other particular embodiments, the 
microneedle may be designed such that the tip portion is only 
a portion of the microneedle that is inserted into the ocular 
25 tissue and generally has a length that is less than about 7 5% of 
the total length of the microneedle, less than about 50% of the 
total length of the microneedle, or less than about 25% of the 
total length of the microneedle. For example, in one embodi-
ment the microneedle has a total effective length between 500 
30 µm and 1000 µm, wherein the tip portion has a length that is 
less than about 400 µm, less than about 300 µm, or less than 
about 200 µm. As used herein, the term "hollow" includes a single, 
straight bore through the center of the microneedle, as well as 
multiple bores, bores that follow complex paths through the 
microneedles, multiple entry and exit points from the bore(s ), 35 
and intersecting or networks of bores. That is, a hollow 
microneedle has a structure that includes one or more con-
tinuous pathways from the base of the microneedle to an exit 
point in the shaft and/or tip portion of the microneedle distal 
Base 
The microneedle extends from a base. The base may be 
integral with or separate from the microneedle. The base may 
be rigid or flexible. The base may be substantially planar or it 
may be curved, for example, in the shape of the ocular tissue 
surface at the site of injection or, for example, curved away 
to the base. 
As used herein, the term "microneedle" refers to a conduit 
body having a base, a shaft, and a tip end suitable for insertion 
into the sclera and other ocular tissue and has dimensions 
suitable for minimally invasive insertion and fluid drug for-
mulation infusion as described herein. That is, the micron-
eedle has a length or effective length that does not exceed 
2000 microns and a width (or diameter) that does not exceed 
500 microns. 
40 from the ocular surface (e.g., convex) so as to minimize 
contact between the base and the ocular tissue. Desirably, the 
base is shaped to provide minimal contact with the surface of 
the eye at the point of insertion. For example, in one embodi-
ment, the base may extend only a minimal distance from the 
45 microneedle shaft substantially perpendicular. In another 
embodiment, the base may be shaped so as to elevate the 
ocular tissue towards the microneedle so as to counteract the 
deflection of the ocular tissue and facilitate insertion of the 
microneedle into the ocular tissue (e.g., the base may extend 
50 from the microneedle toward the tip portion of the micron-
eedle so as to "pinch" the ocular tissue). Some such embodi-
ments may be based, at least in part, on the devices described 
in U.S. Pat. No. 6,743,211, the relevant disclosure of which is 
In various embodiments, the microneedle may have a 
length of about 50 µm to 2000 µm. In another particular 
embodiment, the microneedle may have a length of about 150 
µm to about 1500 µm, about 300 µm to about 1250 µm, about 
500 µm to about 1250 µm, about 700 µm to about 1000 µm, or 
about 800 to about 1000 µm. In a preferred embodiment, the 
length of the microneedle is about 1000 µm. In various 55 
embodiments, the proximal portion of the microneedle has a 
maximum width or cross-sectional dimension of about 50 µm 
incorporated herein by reference. 
In a particular embodiment, the microneedle device has a 
single microneedle. In one embodiment, illustrated in FIG. 5, 
the microneedle device 130 includes a convex base 132 and a 
hollow microneedle 134 which has a bore 140 through which 
a fluid drug formulation (not shown) can be delivered to the 
to 500 µm, about 50 µm to about 400 µm, about 100 µm to 
about 400 µm, about 200 µm to about 400 µm, or about 100 
µm to about 250 µm, with an aperture diameter of about 5 µm 
to about 400 µm. In a particular embodiment, the proximal 
portion of the microneedle has a maximum width or cross-
sectional dimension of about 400 µm. Those skilled in the art 
will appreciate, however, that in embodiments in which the 
tip of the microneedle is beveled that the aperture diameter 
may be greater than the outer diameterof the proximal portion 
of the microneedle. The microneedle may be fabricated to 
60 eye or through which a biological fluid can be withdrawn 
from the eye. The hollow microneedle 134 includes a proxi-
mal portion 136 and a tip portion 138. 
The microneedle may extend from the base of the micron-
eedle device at any angle suitable for insertion into the eye. In 
65 a particular embodiment, the microneedle extends from the 
base at an angle of about 90 degrees to provide approximately 
perpendicular insertion of the microneedles into the surface 
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of the eye. In another particular embodiment, the microneedle 
extends from the base at an angle from about 60 to about 90 
degrees. 
Microneedle Arrays 
In an alternative embodiment, the device includes an array 
of two or more microneedles. For example, the device may 
include an array of between 2 and 1000 (e.g., between 2 and 
100) microneedles. In one embodiment, a device may include 
between 1 and 10 microneedles. An array of microneedles 
may include a mixture of different microneedles. For 
instance, an array may include microneedles having various 
lengths, base portion diameters, tip portion shapes, spacings 
between microneedles, drug coatings, etc. In embodiments 
wherein the microneedle device comprises an array of two or 
more microneedles, the angle at which a single microneedle 
extends from the base may be independent from the angle at 
which another microneedle in the array extends from the 
base. 
Exemplary Devices 
FIGS. 2-5 illustrate exemplary embodiments of micron-
eedle devices. In one embodiment, illustrated in FIG. 2-3, the 
microneedle device 110 includes a hollow microneedle 114 
having a hollow bore 140 through which a fluid drug formu-
lation (not shown) can be delivered to the eye or through 
which a biological fluid can be withdrawn from the eye. The 
microneedle includes a proximal portion 116 and a tip portion 
118. The microneedle 114 may extend from a base compris-
ing, for example, an elongated body 112 having a distal end 
from which the proximal portion 116 and tip portion 118 of 
the microneedle extends. The elongated body may further 
comprise a means for securing 111 a base portion of the 
microneedle extending beyond the distal end of the base 112, 
such as a screw or pin. An exemplary embodiment of the 
elongated body 112 for securing the microneedle is illustrated 
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and copolymers and blends thereof. Representative non-bio-
degradable polymers include various thermoplastics or other 
polymeric structural materials known in the fabrication of 
Medical devices. Examples include nylons, polyesters, poly-
carbonates, polyacrylates, polymers of ethylene-vinyl 
acetates and other acyl substituted cellulose acetates, non-
degradable polyurethanes, polystyrenes, polyvinyl chloride, 
polyvinyl fluoride, poly(vinyl imidazole), chlorosulphonate 
polyolefins, polyethylene oxide, blends and copolymers 
10 thereof. Biodegradable microneedles can provide an 
increased level of safety compared to non-biodegradable 
ones, such that they are essentially harmless even if inadvert-
ently broken off into the ocular tissue. 
The microneedle can be fabricated by a variety of methods 
15 known in the art or as described in the Examples below. In one 
embodiment, the hollow microneedle is fabricated using a 
laser or similar optical energy source. In one example, a 
microcarnmla may be cut using a laser to represent the desired 
microneedle length. The laser may also be use to shape single 
20 or multiple tip openings. Single or multiple cuts may be 
performed on a single microcarnmla to shape the desired 
microneedle structure. In one example, the microcannula 
may be made of metal such as stainless steel and cut using a 
laser with a wavelength in the infrared region of the light 
25 spectrum (0.7-300 µm). Further refinement may be per-
formed using metal electropolishing techniques familiar to 
those in the field. In another embodiment, the microneedle 
length and optional bevel is formed by a physical grinding 
process, which for example may include grinding a metal 
30 carnmla against a moving abrasive surface. The fabrication 
process may further include precision grinding, micro-bead 
jet blasting and ultrasonic cleaning to form the shape of the 
desired precise tip of the microneedle. 
Further details of possible manufacturing techniques are 
35 described, for example, in U.S. Patent Application Publica-
tion No. 2006/0086689 Al to Raju et al., U.S. Patent Appli-
cation Publication No. 2006/0084942 to Kim et al., U.S. 
Patent Application Publication No. 2005/0209565 to Yuzha-
kov et al., U.S. Patent Application Publication No. 20021 
in FIG. 3, and comprises a cap portion 113 and a base portion 
115 having a hollow bore 117 therein. The cap portion 113 
and base portion 115 of the elongated body 112 desirably 
comprise a means for manually adjusting the length of needle 
(i.e., the proximal portion and tip portion of the microneedle 
extending from the base 112) protruding out of the cap por-
tion of the elongated body. Such means may include, for 
example, threads 119 allowing the cap portion 113 to be 
screwed in and out of the base portion 115 of the elongated 
body. In an exemplary embodiment illustrated in FIG. 4, the 
base portion 115 of the elongated body may be operably 45 
connected to an actuator 120 for controlled infusion of the 
fluid drug formulation through the microneedle into the 
suprachoroidal space. 
40 0082543 Al to Park et al., U.S. Pat. No. 6,334,856 to Allen et 
al., U.S. Pat. No. 6,611,707 to Prausnitz et al., U.S. Pat. No. 
6,743,211 to Prausnitz et al., all of which are incorporated 
herein by reference for their disclosure of microneedle fabri-
cation techniques. 
Fluid Drug Formulation 
The fluid drug formulation may be in the form of a liquid 
drug, a liquid solution that includes a drug in a suitable 
solvent, or liquid suspension. The liquid suspension may 
include microparticles or nanoparticles dispersed in a suitable The microneedle device may further comprise a fluid res-
ervoir for containing the fluid drug formulation, the fluid drug 
reservoir being in operable communication with the bore of 
the microneedle at a location distal to the tip end of the 
microneedle. The fluid reservoir may be integral with the 
microneedle, integral with the elongated body, or separate 
from both the microneedle and elongated body. 
Fabrication of the Microneedles 
The microneedle can be formed/constructed of different 
biocompatible materials, including metals, glasses, semi-
conductor materials, ceramics, or polymers. Examples of 
suitable metals include pharmaceutical grade stainless steel, 
gold, titanium, nickel, iron, gold, tin, chromium, copper, and 
alloys thereof. The polymer can be biodegradable or non-
biodegradable. Examples of suitable biocompatible, biode-
gradable polymers include polylactides, polyglycolides, 
polylactide-co-glycolides (PLGA), polyanhydrides, poly-
orthoesters, polyetheresters, polycaprolactones, polyestera-
mides, poly(butyric acid), poly(valeric acid), polyurethanes 
50 liquid vehicle for infusion. In various embodiments, the drug 
may be included in the liquid vehicle, in the microparticles or 
nanoparticles, or in both the vehicle and particles. The fluid 
drug formulation is sufficiently fluid to flow into and within 
the suprachoroidal space. In a preferred embodiment, the 
55 viscosity of the fluid drug formulation is about 1 cP at 37° C. 
A wide range of drugs may be formulated for delivery to 
ocular tissues with the present microneedle devices and meth-
ods. As used herein, the term "drug" refers to essentially any 
prophylactic, therapeutic, or diagnostic agent, i.e., an ingre-
60 dient useful for medical, veterinary, or cosmetic applications. 
The drug may be selected from suitable proteins, peptides and 
fragments thereof, which can be naturally occurring, synthe-
sized or recombinantly produced. The drug may be selected 
from suitable oligonucleotides (e.g., antisense oligonucle-
65 otide agents), polynucleotides (e.g., therapeutic DNA), 
ribozymes, dsRNAs, siRNA, RNAi, gene therapy vectors, 
and/or vaccines for therapeutic use. The drug may be an 
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aptamer (e.g., an oligonucleotide or peptide molecule that 
binds to a specific target molecule). 
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gas, or a combination thereof. In one case, the microcapsule 
may be a "microbubble" having an outer shell surrounding a 
core of gas, wherein the drug is disposed on the surface of the 
outer shell, in the outer shell itself, or in the core. (Mi-
cro bubbles may be respond to acoustic vibrations as known in 
the art for diagnosis or to burst the micro bubble to release its 
payload at/into a select ocular tissue site.) "Microspheres" 
can be solid spheres, can be porous and include a sponge-like 
or honeycomb structure formed by pores or voids in a matrix 
10 material or shell, or can include multiple discrete voids in a 
matrix material or shell. The microparticle or nanoparticles 
may further include a matrix material. The shell or matrix 
material may be a polymer, amino acid, saccharide, or other 
Representative examples of types of drugs for delivery to 
ocular tissues include antibiotics, antiviral agents, analgesics, 
anesthetics, antihistamines, anti-inflammatory agents, and 
antineoplastic agents. Non-limiting examples of specific 
drugs and classes of drugs include ~-adrenoceptor antago-
nists (e.g., carteolol, cetamolol, betaxolol, levobunolol, 
metipranolol, timolol), miotics (e.g., pilocarpine, carbachol, 
physostigmine), sympathomimetics (e.g., adrenaline, dipiv-
efrine ), carbonic anhydrase inhibitors (e.g., acetazolamide, 
dorzolamide), prostaglandins, anti-microbial compounds, 
including anti-bacterials and anti-fungals (e.g., chloram-
phenicol, chlortetracycline, ciprofloxacin, framycetin, 
fusidic acid, gentamicin, neomycin, norfloxacin, ofloxacin, 15 
polymyxin, propamidine, tetracycline, tobramycin, quino-
lines ), anti-viral compounds (e.g., acyclovir, cidofovir, 
idoxuridine, interferons), al dose reductase inhibitors, anti-
inflammatory and/or anti-allergy compounds (e.g., steroidal 
compounds such as betamethasone, clobetasone, dexametha-
sone, fluorometholone, hydrocortisone, prednisolone and 
non-steroidal compounds such as antazoline, bromfenac, 
diclofenac, indomethacin, lodoxamide, saprofen, sodium 
cromoglycate), artificial tear/dry eye therapies, local anes-
thetics (e.g., amethocaine, lignocaine, oxbuprocaine, proxyr-
netacaine ), cyclosporine, diclofenac, urogastrone and growth 
factors such as epidermal growth factor, mydriatics and 
cycloplegics, mitomycin C, and collagenase inhibitors and 
treatments of age-related macular degeneration such as 
pegagtanib sodium, ranibizumab, and bevacizumab. 
material known in the art of microencapsulation. 
The drug-containing microparticles or nanoparticles may 
be suspended in an aqueous or non-aqueous liquid vehicle. 
The liquid vehicle may be a pharmaceutically acceptable 
aqueous solution, and optionally may further include a sur-
factant. The microparticles or nanoparticles of drug them-
20 selves may include an excipient material, such as a polymer, 
a polysaccharide, a surfactant, etc., which are known in the art 
to control the kinetics of drug release from particles. 
In one embodiment, the fluid drug formulation further 
includes an agent effective to degrade collagen or GAG fibers 
25 in the sclera, which may enhance penetration/release of the 
drug into the ocular tissues. This agent may be, for example, 
an enzyme, such a hyaluronidase, a collagenase, or a combi-
nation thereof. In a variation of this method, the enzyme is 
administered to the ocular tissue in a separate step from-
30 preceding or following-infusion of the drug. The enzyme 
and drug are administered at the same site. In certain embodiments the drug may be an integrin 
antagonist, a selectin antagonist, an adhesion molecule 
antagonist (e.g., Intercellular Adhesion Molecule (ICAM)-1, 
ICAM-2, ICAM-3, Platelet Endothelial Adhesion Molecule 
(PCAM), Vascular Cell Adhesion Molecule (VCAM)), or a 
leukocyte adhesion-inducing cytokine or growth factor 
antagonist (e.g., Tumor Netictosis Factor-a (TNF-a), Inter-
leukin-I~ (IL-I~), Monocyte Chemotatic Protein-I (MCP-1) 
and a Vascular Endothelial Growth Factor (VEGF)), as 
described in U.S. Pat. No. 6,524,581 to Adamis. In certain 40 
other embodiments, the drug may be sub-immunoglobulin 
antigen-binding molecules, such as Fv immunoglobulin frag-
ments, minibodies, and the like, as described in U.S. Pat. No. 
In another embodiment, the drug formulation is one which 
undergoes a phase change upon administration. For instance, 
a liquid drug formulation may be injected through hollow 
35 microneedles into the suprachoroidal space, where it then 
gels and the drug diffuses out from the gel for controlled 
release. 
6, 773,916 to Thiel et al. In another embodiment, the drug may 
be a diagnostic agent, such as a contrast agent, known in the 45 
art. 
Control Features for Directing Movement of the Micron-
eedle in the Methods of Use 
The microneedle device may comprise a means for con-
trollably inserting, and optionally retracting, the microneedle 
into the ocular tissue. In addition, the microneedle device may 
include means of controlling the angle at which the at least 
one microneedle is inserted into the ocular tissue (e.g., by 
inserting the at least one microneedle into the surface of the 
ocular tissue at an angle of about 90 degrees). 
The depth of microneedle insertion into the ocular tissue 
can be controlled by the length of the microneedle, as well as 
other geometric features of the microneedle. For example, a 
flange or other a sudden change in microneedle width can be 
used to limit the depth of microneedle insertion. The micron-
eedle insertion can also be controlled using a mechanical 
micropositioning system involving gears or other mechanical 
components that move the microneedle into the ocular tissue 
The drug typically needs to be formulated for storage and 
delivery via the microneedle device described herein. The 
"drug formulation" is a formulation of a drug, which typically 
includes one or more pharmaceutically acceptable excipient 50 
materials known in the art. The term "excipient" refers to any 
non-active ingredient of the formulation intended to facilitate 
handling, stability, dispersibility, wettability, release kinetics, 
and/or injection of the drug. In one embodiment, the excipient 
may include or consist of water or saline. 
In one embodiment, the fluid drug formulation includes 
microparticles or nanoparticles, either of which includes at 
least one drug. Desirably, the microparticles or nanoparticles 
provide for the controlled release of drug into the ocular 
tissue. As used herein, the term "microparticle" encompasses 60 
microspheres, microcapsules, microparticles, and beads, hav-
ing a number average diameter of I to I 00 µm, most prefer-
ably I to 25 µm. The term "nanoparticles" are particles having 
55 a controlled distance and, likewise, can be operated, for 
example, in reverse, to retract the microneedle a controlled 
distance. The depth of insertion can also be controlled by the 
velocity at which the microneedle is inserted into the ocular 
a number average diameter of I to 1000 nm. Microparticles 
may or may not be spherical in shape. "Microcapsules" are 65 
defined as microparticles having an outer shell surrounding a 
core of another material. The core can be liquid, gel, solid, 
tissue. The retraction distance can be controlled by elastic 
recoil of the ocular tissue into which the microneedle is 
inserted or by including an elastic element within the micron-
eedle device that pulls the microneedle back a specified dis-
tance after the force of insertion is released. 
The angle of insertion can be directed by positioning the 
microneedle at a first angle relative to the microneedle base 
and positioning the base at a second angle relative to the 
ocular surface. In one embodiment, the first angle can be 
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about 90° and the second angle can be about 0°. The angle of 
insertion can also be directed by having the microneedle 
protrude from a device housing through a channel in that 
housing that is oriented at a specified angle. 
One skilled in the art may adapt mechanical systems 
known in the art in combination with the disclosure set forth 
herein and in the Examples below to devise suitable structures 
to controllably drive the microneedle insertion, which struc-
tures may be manually operable, electromechanically oper-
able, or a combination thereof. 
Control of Transport Through Microneedle 
The transport of drug formulation or biological fluid 
through a hollow microneedle can be controlled or monitored 
using, for example, one or more valves, pumps, sensors, 
actuators, and microprocessors. For instance, in one embodi-
ment the microneedle device may include a micropump, 
microvalve, and positioner, with a microprocessor pro-
grammed to control a pump or valve to control the rate of 
delivery of a drug formulation through the microneedle and 
into the ocular tissue. The flow through a microneedle may be 
driven by diffusion, capillary action, a mechanical pump, 
electroosmosis, electrophoresis, convection or other driving 
forces. Devices and microneedle designs can be tailored 
using known pumps and other devices to utilize these drivers. 
In one embodiment, the microneedle device may further 
include an iontophoretic apparatus, similar to that described 
in U.S. Pat. No. 6,319,240to Beck, for enhancing the delivery 
of the drug formulation to the ocular tissue. In another 
embodiment the microneedle devices can further include a 
flowmeter or other means to monitor flow through the 
microneedles and to coordinate use of the pumps and valves. 
The flow of drug formulation or biological fluid can be 
regulated using various valves or gates known in the art. The 
valve may be one which can be selectively and repeatedly 
opened and closed, or it may be a single-use type, such as a 
fracturable barrier. Other valves or gates used in the micron-
eedle devices can be activated thermally, electrochemically, 
mechanically, or magnetically to selectively initiate, modu-
late, or stop the flow of material through the microneedles. In 
one embodiment, the flow is controlled with a rate-limiting 
membrane acting as the valve. 
The present invention may be further understood with ref-
erence to the following non-limiting examples. 
EXAMPLES 
Experiments were conducted to evaluate whether micron-
eedles could be used to pierce to the base of the sclera and 
target the suprachoroidal space. More specifically, experi-
ments were conducted to evaluate whether hollow micron-
eedles can deliver small molecules and particles to the supra-
choroidal space of pig, rabbit and human cadaver eyes. 
Additional experiments were conducted to measure the effect 
of microneedle length, infusion pressure, and intraocular 
pressure on the delivery of particles ranging from 20-1000 nm 
in diameter in pig eyes. Finally, experiments were conducted 
to examine the role that particle size plays and the influence of 
ocular anatomical barriers on delivery to the suprachoroidal 
space. 
Whole rabbit eyes (Pel-Freez Biologicals, Rogers, Ark.), 
pig eyes (Sioux-Preme Packing, Sioux Center, Iowa) and 
human eyes (Georgia Eye Bank, Atlanta, Ga.), all with the 
optic nerve attached, were shipped on ice and stored wet at 4 ° 
C. for up to 3 days. Prior to use, eyes were allowed to come to 
room temperature and any fat and conjunctiva were removed 
to expose the sclera. 
16 
Hollow microneedles were fabricated from borosilicate 
micropipette tubes (Sutter Instrument, Novato, Calif.), as 
described previously (J. Jiang, et al., Pharm. Res. 26:395-403 
(2009)). FIG. 7A shows a comparison of the hollow micron-
eedle compared to the tip of a 30 gauge hypodermic needle 
(scale=500 µm). A custom, pen-like device with a threaded 
cap was fabricated to position the microneedle and allow 
precise adjustment of its length. This device was attached to a 
micropipette holder (MMP-KIT, World Precision Instru-
lO ments, Sarasota, Fla.) with tubing that was connected to a 
carbon dioxide gas cylinder for application of infusion pres-
sure. The holder was attached to a micromanipulator (KITE, 
World Precision Instruments) which was used to control 
15 insertion of the microneedle into the sclera. 
Carboxylate-modified FluoSpheres® (Invitrogen, Carls-
bad, Calif.) were injected as 2 wt% solids suspension of 20 
nm, 100 nm, 500 nm, and 1000 nm diameter particles. Tween 
80 (Sigma-Aldrich, St. Louis, Mo.) at a final concentration of 
20 0.5 wt%, was added to the suspension and sonicated prior to 
use. Sulforhodamine B (Sigma-Aldrich) was dissolved in 
Hanks' balanced salt solution (Mediatech, Manassas, Va.) to 
make a sulforhodamine solution of 10-4 M. Barium sulfate 
particles (Fisher Scientific, Waltham, Mass.) measuring 1 µm 
25 in diameter were suspended in balanced salt solution (BSS 
Plus, Alcon, Fort Worth, Tex.) to form a 1.5 wt% suspension. 
A custom acrylic mold, shaped to fit a whole eye, was built 
to hold the eye steady and used for all experiments (FIG. 7B). 
A catheter was inserted through the optic nerve into the vit-
30 reous and connected to a bottle ofBSS Plus raised to a height 
to generate internal eye pressure (18 or 36 mm Hg). Suction 
was applied to a channel within the mold to hold the external 
surface of the eye steady during microneedle insertion and 
manipulation. Each microneedle was pre-filled with a desired 
35 volume of the material to be injected. The microneedle was 
placed in the device holder at a set microneedle length, 
attached to the micromanipulator and connected to the con-
stant pressure source. Microneedles were then inserted per-
pendicular to the sclera tissue 5-7 mm posterior from the 
40 limbus. A set pressure was applied to induce infusion. Thirty 
seconds were allowed to see ifinfusion of the solution began. 
If infusion occurred, the pressure was stopped immediately 
upon injection of the specified volume. If visual observation 
of the injected material showed localization in the supracho-
45 roidal space, the injection was considered a success. If infu-
sion had not begun within that timeframe, then the applied 
pressure was stopped and the needle was retracted. This was 
considered an unsuccessful delivery. 
Eyes to be imaged using microscopy were detached from 
50 the set-up within minutes after delivery was completed. The 
eyes were placed in acetone or isopentane kept on dry ice or 
liquid nitrogen, causing the eye to freeze completely within 
minutes after placement. The frozen eye was removed from 
the liquid and portions of the eye were hand cut using a razor 
55 blade for imaging of injected material. Imaging was per-
formed using a stereo microscope using brightfield and fluo-
rescence optics (model SZX 12, Olympus America, Center 
Valley, Pa.). The portions containing the sclera, choroid and 
retina were placed in Optimal Cutting Temperature media 
60 (Sakura Finetek, Torrance, Calif.) and frozen under dry ice or 
liquid nitrogen. These samples were cryosectioned 10-30 µm 
thick (Microm Cryo-Star HM 560MV, Walldorf, Germany) 
and imaged by brightfield and fluorescence microscopy (Ni-
kon E600, Melville, N.Y.) to determine the location of 
65 injected material in the eye. Images were collaged as neces-
sary using Adobe Photoshop software (Adobe Systems, San 
Jose, Calif.). 
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insertion site, the injection had spread approximately 20 mm, 
which corresponds to about 36% of the total circumference of 
the eye. 
Pig eyes used for microcomputed tomography imaging 
were not frozen after injection. Instead, pig eyes were injected 
with a barium sulfate suspension and stabilized in a 30 mm 
diameter sample tube and scanned in air using a Scanco 
µCT40 desktop conebeam system (Scam) Medical AG, Briit-
tisellen, Switzerland) at 30 µm isotropic voxel size, E=55 
kVp, I=145 µA, and integration time=200 ms. Through a 
convolution backprojection algorithm based on techniques 
from Feldkamp et. al. (J. Opt. Soc. AM. A-Opt. Image Sci. Vis. 
1:612-619 (1984)), raw data were automatically recon-
structed to generate 2D grayscale tomograms. Global seg-
mentation values (Gauss sigma, Gauss support, and thresh-
old) were chosen for the contrast-enhanced region as well as 
general eye tissue. Grayscale tomograms were stacked, and 
3D binarized images were produced by applying the optimal 
segmentation values (one image for the entire eye and another 
for the region injected with contrast agent). These images 
were overlayed using Scanco image processing language to 
demonstrate the relative 3D position of the contrast-enhanced 
region within the entire eye. 
Fluoroscopic images of cryosections of pig and human 
eyes were taken in the sagittal directions so that the images 
show the anteriorofthe eye to theright and the posterior of the 
eye to the left (FIGS. 9C and 9D, respectively). These images 
show the ability of microinjected particles (which appear 
bright white) to spread in the suprachoroidal space both in the 
10 
anterior and posterior direction of the eye from the injection 
site. In these experiments, a single microneedle delivered 30 
µL of a 2 wt % particle suspension into the suprachoroidal 
space of both species. Leakage was observed at the vortex 
15 vein openings away from the injection site similar to what was 
observed with sulforhodamine injections. 
The insets in these images show magnified views of the 
microneedle insertion site. In each case, the insertion site 
within the sclera was filled with particles. In the case of the 
Example 1 
Delivery of a Model Compound to the 
Suprachoroidal Space Using a Hollow Microneedle 
20 pig (FIG. 9C) and human (FIG. 9D), the retina was still 
attached and visible, and it was clear that the microneedle had 
not penetrated to the retina. In the case of the rabbit (FIG. 9B ), 
the retina separated during the cryosectioning procedure and 
was not visible. These results confirmed that a microneedle 
25 was able to target the suprachoroidal space of rabbit, pig, and 
human eyes to deliver particles up to 1000 nm in diameter. 
The results further confirmed that these particles spread from 
the injection site circumferentially in all directions within the 
Red-fluorescent sulforhodamine B was used as a model 
compound and injected into pig eyes ex vivo using a single 
hollow microneedle inserted just to the base of the sclera in 
order to target the suprachoroidal space. A brightfield micro- 30 
scopic image of the saggital cross section of an untreated pig 
eye, shown in FIGS. SA and SB (Scale bar: 500 µm), was 
taken both before and after injection of 35 µL of sulfor-
hodamine B. The normal ocular tissue (FIG. SA) can be 
distinguished to identify the sclera, choroid, retina, and vit-
reous humor. After infusion of the model compound (FIG. 
SB), the sulforhodamine solution can be seen just below the 
sclera and above the choroid in the suprachoroidal space, 
confirming that the solution was injected and spread within 
the suprachoroidal space from the initial injection site. Vol-
umes up to 35 µL were able to be injected without leakage, but 
larger volumes leaked out from openings on the surface of the 
eye where vortex veins would be attached in vivo. However, 
subsequent experiments in pigs and rabbits in vivo have dem-
onstrated suprachoroidal delivery of up to 100 µL without 
leakage through these openings (data not shown). 
suprachoroidal space. 
Microcomputed tomography (µCT) was utilized to image 
the circumferential spread and localization of injected mate-
rial in the suprachoroidal space in three dimensions using a 
noninvasive method. After injecting 35 µL of 1 µm diameter 
barium sulfate contrast agent particles into the suprachoroidal 
35 space of a pig eye, cross sectional images showed the particles 
distributed as a thin white strip that circled just below the 
outer edge of the eye, i.e., just below the sclera (FIG. lOA). 
This profile is characteristic of suprachoroidal delivery and 
similar to the results from fluorescence imaging. The three-
40 dimensional reconstruction of these cross-sectional images 
showed the spread of the particles in the posterior segment of 
the eye (FIG. lOB, Scale Bar: 5 mm). The particles spread was 
approximately 5 mm in radius, although asymmetrically dis-
tributed around the injection site, and covered an approximate 
Example 2 
45 area of 70 mm2 (which represents 7% of the surface area of 
the back of the eye). This further confirmed the ability of 
microneedles to spread particles over a significant portion of 
the posterior segment of the eye by targeting the suprachor-
oidal space. 
Delivery of Particles to the Suprachoroidal Space 
Using Hollow Microneedles 
50 
Particles with diameters of 500 nm or 1000 nm were 
injected into the suprachoroidal space of rabbit, pig and 
human eyes ex vivo and imaged to evaluate the distribution 55 
and localization of the particles just below the sclera. The 
sclera (1), choroid (2), and retina (3) were identified in a 
fluoroscopic image of a cryosection of a pig eye with no 
infusion into the suprachoroidal space (FIG. 9A, Scale bar: 
500 µm). Fluoroscopic images of cryosections of a rabbit eye 60 
after injection of 500 nm particles were taken in the axial 
plane and the images were collaged to form a panoramic view 
(FIG. 9B, Scale bar: 500 µm). The spread of the fluorescent 
particles (which appear as the bright white regions in the 
images) was observed along the equator of the eye in a thin 65 
sheath just below the sclera. A volume of 15 µL was injected 
and, in this particular cross-section taken in the plane of the 
Example 3 
Effect of Operating Parameters on Particle Delivery 
to the Suprachoroidal Space 
Particles of 20, 100, 500, and 1000 nm diameter were 
injected into pig eyes ex vivo using a range of different 
microneedle lengths and infusion pressures to determine the 
success rate of suprachoroidal delivery. An attempted injec-
tion was considered to be either fully successful (complete 
injection of the 25 µL particle suspension into the supracho-
roidal space) or fully unsuccessful (an inability to inject at 
all). No partial injections were observed. The effect of infu-
sion pressure and microneedle length on the success rate of 
suprachoroidal delivery of particles are shown for 20 nm 
(FIG. llA), 100 nm (FIG. llB), 500 nm (FIG. llC), and 
1000 nm (FIG. llD) particles into pig eyes. 
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The success rate increased with greater infusion pressure 
and with greater microneedle length (ANOVA, p<0.05). For 
the 20 nm particles (FIG. llA), 100% successful injections 
were achieved using a pressure of250 kPa at all microneedle 
lengths. For 100 nm particles (FIG. llB), the effects of pres-
sure similarly plateaued at 250 kPa and 100% success was 
achieved at all but the shortest microneedle length (700 µm). 
For the larger particles (500 and 1000 nm) (FIGS. llC and 
llD, respectively), the effects of pressure generally plateaued 
at 300 kPa and success rate significantly decreased for shorter 10 
microneedles. Not wishing to be bound by any theory, it is 
believed that short microneedles lengths inject within the 
sclera, such that particles must be forced through a portion of 
the sclera to reach the suprachoroidal space. Smaller particles 15 (20 and 100 nm) can more easily force through a portion of 
the sclera to reach the suprachoroidal space because the spac-
ing of collagen fiber bundles in the sclera is on the order of 
300 nm. Larger particles (500 and 1000 nm), however, have 
more difficulty crossing this anatomical barrier, such that 20 
infusion pressure becomes a more important parameter and 
injection success rate decreases significantly. 
A statistical comparison of the injection rates of particles 
of different sizes at different microneedle lengths was made 
using AN OVA and is summarized in the following table. 25 
Micro needle 20 vs 100 vs 500 vs 20 vs 
Length lOOnm 500nm 1000 nm 1000 nm 30 
700 µm 0.02* 0.02* 0.09 0.02* 
800 µm 0.37 0.00* 0.10 0.01 * 
900 µm 0.18 0.03* 0.18 0.03* 
1000 µm 0.18 0.37 0.21 0.18 
Significance was considered to be a p < 0.05 and indicated by an asterisk(*). 35 
The statistical analysis showed that at a microneedle length of 
700 µm, where the most scleral tissue must be traversed to 
reach the suprachoroidal space, success rate depended 
strongly on particle size. Using 800 and 900 µm micron- 40 
eedles, particles smaller than the collagen fiber spacing (20 
and 100 nm) behaved similarly and particles larger than the 
collagen fiber spacing (500 and 1000 nm) also behaved simi-
larly, but there was a significant difference between 100 nm 
and 500 nm particles. The longest microneedles (1000 µm), 45 
which probably reached the base of the sclera, showed no 
significant dependence on particle size, suggesting that over-
coming the collagen barrier in the sclera was no longer 
needed. 
20 
Example 4 
Effect of Intraocular Pressure on Delivery of 
Particles to the Suprachoroidal Space 
Intraocular Pressure (IOP) is the internal pressure within 
the eye that keeps the eye inflated. It provides a back pressure 
that can counteract the infusion pressure. To evaluate the 
effect ofintraocular pressure on particle delivery to the supra-
choroidal space, 1000 nm particles were injected at two dif-
ferent levels ofIOP, 18 and 36 mmHg. The effect of infusion 
pressure and microneedle length on the success rate of supra-
choroidal delivery of 1000 nm particles at simulated IOP 
levels of 18 mmHg and 36 mmHg is shown in FIG. 13A and 
FIG. 13B, respectively. The delivery success rate generally 
increased with an increase in IOP. Notably, at normal IOP, no 
particles were delivered at the lowest infusion pressure (150 
kPa) orusing the shortest microneedles (700 µm) and only the 
longest microneedles (1000 µm) achieved 100% success rate 
at the highest infusion pressure (300 kPa) (FIG. 13A). In 
contrast, at elevated IOP, particles were sometimes delivered 
at the lowest infusion pressure and using the shortest micron-
eedles, and a 100% success rate was achieved using both 900 
and 1000 µm microneedles at the highest infusion pressure 
(FIG.13B). 
Not wishing to be bound by any theory, it is believed that 
the main effect of elevated IOP is to make the sclera surface 
more firm, reducing tissue surface deflection during micron-
eedle insertion and thereby increasing the depth of penetra-
tion into sclera for a microneedle of a given length. Although 
we did not measure microneedle insertion depth directly, 
these results suggest that microneedle insertion may be more 
effective at elevated IOP because they insert deeper into the 
sclera and thereby increase infusion success rate. 
Example 5 
Delivery of Model Compound to Suprachoroidal 
Space in Live Animal Models 
The delivery of a fluorescent molecule (sodium fluores-
cein) to the suprachoroidal space was evaluated using rabbits 
according to approved live animal experimental protocols. A 
one dimensional scan of the eye (through line of sight) was 
taken within the first five minutes after injection to determine 
the dispersion of the fluorescent molecule in the eye (FIG. 
14). The y-axis indicates the fluorescent intensity (i.e., the 
concentration) and the x-axis represents the position in the 
eye from front (160) to back (0). Thus, the results illustrate 
that within the first 5 minutes after injection, the fluorescein 
had already flowed through the suprachoroidal space to the 
50 back of the eye, with some remaining at the initial insertion Not wishing to be bound by any particular theory, the 
foregoing further suggested that particles of 20 and 100 nm 
can spread within the sclera as well as the suprachoroidal 
space, whereas particles of 500 and 1000 nm should localize 
exclusively in the suprachoroidal space. The spread of 20 nm 
particles (FIG. 12A) was compared to the spread of 1000 nm 55 
particles (FIG. 12B) under identical conditions. As expected, 
the smaller particles exhibited significant spread in the sclera 
as well as the suprachoroidal space. In contrast, the larger 
particles were relegated primarily to the suprachoroidal space 
and were largely excluded from the sclera. This localization 60 
of large particles was consistent with the results shown in 
FIG.11. 
Thus, 20 and 100 nm particles were reliably injected using 
a minimum microneedle length of 800 µm and a minimum 
pressure of 250 kPa. To deliver 500 and 1000 nm particles, a 65 
minimum microneedle length of 1000 µm and a minimum 
pressure of 250-300 kPa was required. 
site. 
Similar scans were taken to evaluate the rate of clearance of 
fluorescein from the suprachoroidal space over time (FIG. 
15). The fluorescent intensity was measured in two regions of 
the eye (the suprachoroidal space and mid-vitreous region) 
over time. The results illustrate that the bulk of the material 
injected remains in the suprachoroidal space without passing 
into the mid-vitreous region and that the material substan-
tially cleared the suprachoroidal space within 24 hours. 
Example 6 
Delivery of Particles to Suprachoroidal Space in Live 
Animal Models 
Live animal experiments also were conducted to evaluate 
the delivery of particles to the suprachoroidal space. Fluores-
US 8,636,713 B2 
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cent particles having a diameter of 20 nm and 500 nm were 
infused into rabbit eyes and the fluorescent intensity was 
evaluated to determine the length of time the particles 
remained in two regions of the eye (the suprachoroidal space 
and mid-vitreous region). 
The small er particles (FIG.16) were successfully delivered 
to the suprachoroidal space and remained in the suprachoroi-
dal space for at least 35 days. The larger particles (FIG. 17) 
also were successfully delivered to the suprachoroidal space 
and remained in the suprachoroidal space for at least 24 days. 10 
Notably, both the smaller and larger particles were well local-
ized as indicated by the low level of fluorescence in the 
mid-vitreous region. 
22 
11. The method of claim 1, wherein the fluid drug formu-
lation comprises a suspension of microparticles or nanopar-
ticles, the microparticles or nanoparticles comprising the 
anti-inflammatory drug. 
12. The method of claim 11, wherein the suspension further 
comprises a physiologically acceptable aqueous vehicle. 
13. The method of claim 1, wherein the fluid drug formu-
lation comprises a formulation that undergoes a phase change 
after being infused into the suprachoroidal space. 
14. The method of claim 1, wherein the step of infusing 
comprises driving the fluid drug formulation at an infusion 
pressure of at least 150 kPa. 
15. The method of claim 1, wherein the step of infusing 
comprises driving the fluid drug formulation at an infusion 
pressure of at least 300 kPa. 
16. The method of claim 1, wherein the microneedle has an 
effective length between 500 microns and 1000 microns. 
Pu?lications ci~ed herein and the materials for which they 
are cited are specifically incorporated by reference. Modifi- 15 
cations and variations of the methods and devices described 
herein will be obvious to those skilled in the art from the 
foregoing detailed description. Such modifications and varia-
tions are intended to come within the scope of the appended 
claims. 
17. The method of claim 1, wherein the microneedle has an 
20 effective length between 700 microns and 1000 microns. 
18. The method of claim 1, wherein the microneedle has an 
effective length between 800 microns and 1000 microns. 
We claim: 
1. A method of administering an anti-inflammatory drug to 
an eye of a patient, comprising: 
inserting a hollow microneedle into the eye at an insertion 
site, the hollow olid microneedle comprising a tip end 
with an opening; and 
19. The method of claim 1, wherein the portion of the 
microneedle that is inserted into the sclera has a maximum 
25 cross-sectional width or diameter of 400 microns. 
20. The method of claim 1, wherein the microneedle is 
formed of metal and has a total effective length between 500 
microns and 1000 microns, the microneedle comprising a 
cylindrical shaft having an outer diameter of between 200 
infusing over a period of time an anti-inflammatory drug 
formulation comprising an anti-inflammatory drug 
through the inserted microneedle and into the supracho-
roidal space of the eye, wherein during the period the 
infused drug formulation flows within the suprachoroi-
dal space away from the insertion site. 
30 microns and 400 microns, and a beveled tip less than about 
400 microns in length. 
2. The method of claim 1, wherein during the period the 
infused fluid drug formulation flows at least 5 mm away from 
the insertion site. 
3. The method of claim 1, wherein the insertion site is at 
about the equator of the eye. 
4. The method of claim 1, wherein the insertion site is 
between the equator and the limbus of the eye. 
35 
5. The method of claim 1, wherein at least a portion of the 40 
anti-inflanimatory drug formulation reaches ocular tissue 
posterior to the equator of the eye during the period. 
6. The method of claim 1, wherein the microneedle is 
inserted into the surface of the sclera at an angle of about 90 
degrees. 
7. The method of claim 1, wherein the tip end of the 
microneedle is inserted substantially to the base of the sclera 
without completely penetrating through the sclera. 
45 
8. The method of claim 1, wherein the tip end of the 
microneedle is inserted through the sclera into the supracho- 50 
roidal space without penetrating through the choroid. 
21. The method of claim 1, wherein the microneedle 
extends substantially perpendicularly from a planar or convex 
base. 
22. The method of claim 1, wherein the patient is in need of 
treatment ofuveitis, glaucoma, diabetic retinopathy, diabetic 
macul.ar edema, wet or dry age-related macular degeneration, 
chor01dal neovascularization, or cytomegalovirus retinitis. 
23. The method of claim 1, wherein the inserting step 
comprises inserting the hollow microneedle into the sclera. 
24. The method of claim 1, wherein the anti-inflammatory 
drug is a steroidal compound. 
25. The method of claim 1, wherein the anti-inflammatory 
drug is a non-steroidal compound. 
26. The method of claim 1, wherein the anti-inflammatory 
drug is a cytokine antagonist. 
27. The method of claim 24, wherein the steroidal com-
pound is betamethasone, clobetasone, dexamethasone, fluo-
rometholone, hydrocortisone or prednisolone. 
28. The method of claim 25, wherein the non-steroidal 
compound is antazoline, bromfenac, diclofenac, indometha-
cin, lodoxamide, saprofen, or sodium cromoglycate . 
29. The method of claim 26, wherein the cytokine is tumor 
necrosis factor alpha. 
. 9. The .method of claim 1, further comprising using 
1maged-gmded feedback to determine the location of the 
microneedle in the eye and/or the location of infused fluid 
drug formulation within the eye. 55 30. The method of claim 27, wherein the cytokine is inter-leukin-I beta. 10. The method of claim 1, wherein from about 10 µL to 
about 200 µL of the fluid drug formulation is infused. 
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